Psoriasis
Páginas: 2 (383 palabras)
Publicado: 4 de noviembre de 2012
The
new england journal
of
medicine
original article
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Mark Lebwohl, M.D., Stephen K. Tyring, M.D., Ph.D., Tiffani K.Hamilton, M.D., Darryl Toth, M.D., Scott Glazer, M.D., Naji H. Tawfik, M.D., Ph.D., Patricia Walicke, M.D., Ph.D., Wolfgang Dummer, M.D., Xiaolin Wang, Sc.D., Marvin R. Garovoy, M.D., and DavidPariser, M.D., for the Efalizumab Study Group
abstract
background
From the Mt. Sinai School of Medicine, New York (M.L.); the University of Texas Medical Branch, Galveston (S.K.T.); the AtlantaDermatology, Vein, and Research Center, Alpharetta, Ga. (T.K.H.); Probity Medical Research, Windsor, Ont., Canada (D.T.); Buffalo Grove, Ill. (S.G.); the Welborn Clinic, Evansville, Ind. (N.H.T.);Genentech, South San Francisco, Calif. (P.W., W.D., X.W.); Xoma, Berkeley, Calif. (M.R.G.); and the Eastern Virginia Medical School and Virginia Clinical Research, Norfolk, Va. (D.P.). Address reprintrequests to Dr. Lebwohl at the Mt. Sinai School of Medicine, 5 E. 98th St., 12th Fl., Box 1048, New York, NY 100296574. N Engl J Med 2003;349:2004-13.
Copyright © 2003 Massachusetts Medical Society.Interactions between leukocyte-function–associated antigen type 1 (LFA-1) and intercellular adhesion molecules are important in the pathogenesis of psoriasis. Efalizumab, a humanized monoclonal antibody,binds to the a subunit (CD11a) of LFA-1 and inhibits the activation of T cells.
methods
In a phase 3, multicenter, randomized, placebo-controlled, double-blind study, we assign 597 subjects withpsoriasis to receive subcutaneous efalizumab (1 or 2 mg per kilogram of body weight per week) or placebo for 12 weeks. Depending on the response after 12 weeks, subjects received an additional 12weeks of treatment with efalizumab or placebo. Study treatments were discontinued at week 24, and subjects were followed for an additional 12 weeks.
results
At week 12, there was an improvement of...
new england journal
of
medicine
original article
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Mark Lebwohl, M.D., Stephen K. Tyring, M.D., Ph.D., Tiffani K.Hamilton, M.D., Darryl Toth, M.D., Scott Glazer, M.D., Naji H. Tawfik, M.D., Ph.D., Patricia Walicke, M.D., Ph.D., Wolfgang Dummer, M.D., Xiaolin Wang, Sc.D., Marvin R. Garovoy, M.D., and DavidPariser, M.D., for the Efalizumab Study Group
abstract
background
From the Mt. Sinai School of Medicine, New York (M.L.); the University of Texas Medical Branch, Galveston (S.K.T.); the AtlantaDermatology, Vein, and Research Center, Alpharetta, Ga. (T.K.H.); Probity Medical Research, Windsor, Ont., Canada (D.T.); Buffalo Grove, Ill. (S.G.); the Welborn Clinic, Evansville, Ind. (N.H.T.);Genentech, South San Francisco, Calif. (P.W., W.D., X.W.); Xoma, Berkeley, Calif. (M.R.G.); and the Eastern Virginia Medical School and Virginia Clinical Research, Norfolk, Va. (D.P.). Address reprintrequests to Dr. Lebwohl at the Mt. Sinai School of Medicine, 5 E. 98th St., 12th Fl., Box 1048, New York, NY 100296574. N Engl J Med 2003;349:2004-13.
Copyright © 2003 Massachusetts Medical Society.Interactions between leukocyte-function–associated antigen type 1 (LFA-1) and intercellular adhesion molecules are important in the pathogenesis of psoriasis. Efalizumab, a humanized monoclonal antibody,binds to the a subunit (CD11a) of LFA-1 and inhibits the activation of T cells.
methods
In a phase 3, multicenter, randomized, placebo-controlled, double-blind study, we assign 597 subjects withpsoriasis to receive subcutaneous efalizumab (1 or 2 mg per kilogram of body weight per week) or placebo for 12 weeks. Depending on the response after 12 weeks, subjects received an additional 12weeks of treatment with efalizumab or placebo. Study treatments were discontinued at week 24, and subjects were followed for an additional 12 weeks.
results
At week 12, there was an improvement of...
Leer documento completo
Regístrate para leer el documento completo.